基于细胞的屏幕识别了一种非常强大的口服可用的ABCB1调节器,用于治疗多药性耐药性
Shuai Wang1,2,3, Sai-Qi Wang4, Xiao-Bing Chen4
1Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
Journal of medicinal chemistry
|October 19, 2024
概括
一种新型化合物WS-917通过抑制ABCB1 (也称为P-糖蛋白) 流动而使癌细胞对化疗敏感. 这一发现为克服癌症治疗中的多药耐药性提供了一个有希望的策略.
科学领域:
- 药理学 药理学 是一个学科.
- 药用化学 医学化学
- 癌症生物学 癌症生物学
背景情况:
- 由ABCB1 (P-糖蛋白) 介导的多药性耐药性 (MDR) 是癌症治疗的一个主要挑战.
- 向ABCB1提供了一种可行的策略,以恢复化疗剂的疗效.
研究的目的:
- 通过基于细胞的表型查发现新的ABCB1调节器.
- 描述已识别的化合物WS-917的作用机制和体内疗效.
主要方法:
- 对ABCB1调节器进行基于细胞的表型查.
- 试验室试验包括药物相互作用研究和细胞热转移试验 (CETSA).
- 在相关癌症模型中的体内疗效研究.
主要成果:
- WS-917是一种特里亚[1,5-a]皮里米衍生物,显著使多药耐药SW620/Ad300细胞对帕克利塔塞尔敏感.
- WS-917通过直接结合和稳定载体来抑制ABCB1介导的药物外流.
- WS-917在体内增强了帕克利塔塞尔和抗PD-L1抑制剂的疗效,没有可观察到的毒性.
结论:
- WS-917是一种强大的ABCB1调节器,有可能克服帕克利塔塞尔耐药性.
- 该化合物表现出有利的药理动力学特性和体内疗效.
- WS-917代表了开发针对ABCB1-过度表达癌症的新疗法的一个有前途的领头羊.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


